bluebird bio Announces Second Quarter 2024 Results Call Date
12 Agosto 2024 - 7:00AM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) announced today that it
will host a conference call to discuss second quarter 2024 results
and business updates on August 14, at 8:00 a.m. ET.
To participate in the conference call, please dial +1 (800)
715-9871 (U.S. and Canada) and ask to be joined into the bluebird
call or provide the Conference ID 2776050.
To access the live webcast, please visit the “Events &
Presentations” page within the Investors & Media section of the
bluebird bio website at http://investor.bluebirdbio.com. A replay
of the webcast will be available on the bluebird bio website for 90
days following the event.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give
patients and their families more bluebird days.
Founded in 2010, bluebird has been setting the standard for gene
therapy for more than a decade—first as a scientific pioneer and
now as a commercial leader. bluebird has an unrivaled track record
in bringing the promise of gene therapy out of clinical studies and
into the real-world setting, having secured FDA approvals for three
therapies in under two years. Today, we are proving and scaling the
commercial model for gene therapy and delivering innovative
solutions for access to patients, providers, and payers.
With a dedicated focus on severe genetic diseases, bluebird has
the largest and deepest ex-vivo gene therapy data set in the field,
with industry-leading programs for sickle cell disease,
β-thalassemia and cerebral adrenoleukodystrophy. We custom design
each of our therapies to address the underlying cause of disease
and have developed in-depth and effective analytical methods to
understand the safety of our lentiviral vector technologies and
drive the field of gene therapy forward.
bluebird continues to forge new paths as a standalone commercial
gene therapy company, combining our real-world experience with a
deep commitment to patient communities and a people-centric culture
that attracts and grows a diverse flock of dedicated birds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240812763842/en/
Investors: Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
Media: Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
bluebird bio (NASDAQ:BLUE)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024